✦ LIBER ✦

Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia

✍ Scribed by Lim, S H; Zhang, Y; Wang, Z; Esler, W V; Beggs, D; Pruitt, B; Hancock, P; Townsend, M

Book ID: 110014395
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 92 KB
Volume: 35
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bmt.1704742

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab and autologous stem cell trans

Rituximab and autologous stem cell transplantation for malignant lymphoma after liver transplantation

✍ Sánchez-González, B; Fernández-Abellán, P; Garay, MC Garcia; Villarrubia, B; Pal 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 73 KB

Rituximab long-term maintenance therapy

Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin’s lymphoma

✍ Frank Neumann; Stefani Harmsen; Simona Martin; Ralf Kronenwett; Mustafa Kondakci 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 96 KB

Prolonged nausea and vomiting after high

Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma

✍ J. Randolph Hecht; Tony Lembo; Linnea Chap 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

vomiting after high dose chemotherapy with autologous peripheral stem cell transplantation (PSCT) in the treatment of high risk breast carcinoma patients. 1 Division of Digestive Diseases, Department of METHODS. Patients with high risk breast carcinoma were conditioned with high

Idiopathic pneumonia syndrome after high

Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer

✍ Wong, R; Rondon, G; Saliba, R M; Shannon, V R; Giralt, S A; Champlin, R E; Ueno, 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 136 KB

Rituximab (anti-CD20 monoclonal antibody

Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem cell transplantation

✍ Tsai, D E; Moore, H C F; Hardy, C L; Porter, D L; Loh, E Y; Vaughn, D J; Luger, 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 52 KB

Long-term event-free survivors after hig

Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma

✍ Andreadis, C; Schuster, S J; Chong, E A; Svoboda, J; Luger, S M; Porter, D L; Ts 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 165 KB